Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.56 |
| ▸ | DRD3 | P35462 | 9/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783222 | 0.87 | DRD2 (0.75) | DRD2DRD3KDM4ELMNADRD4 | |
| SCHEMBL9565835 | 0.86 | KDM4E (0.66) | DRD2DRD3KDM4ELMNADRD4 | |
| SCHEMBL2785894 | 0.85 | DRD2 (0.77) | DRD2DRD3DRD4 | |
| SCHEMBL13087951 | 0.83 | GAA (0.65) | KDM4ELMNAALDH1A1GAAHPGD | |
| SCHEMBL11745974 | 0.83 | DRD2 (0.73) | DRD2DRD3KDM4ELMNAALDH1A1 | |
| SCHEMBL2782686 | 0.82 | DRD2 (0.55) | DRD2DRD3KDM4ELMNADRD4 | |
| SCHEMBL2784856 | 0.82 | DRD2 (0.55) | DRD2DRD3KDM4ELMNADRD4 | |
| SCHEMBL2784889 | 0.82 | DRD2 (0.55) | DRD2DRD3KDM4ELMNADRD4 | |
| SCHEMBL2783409 | 0.81 | ADRA2A (0.50) | DRD2DRD3KDM4ELMNADRD4 | |
| SCHEMBL12359055 | 0.81 | DRD2 (0.71) | DRD2DRD3KDM4ELMNADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2010-10-07 | — | — | US | claimed |
| EP-2204363-A1 | New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-07-07 | — | — | EP | claimed |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2007-06-28 | — | — | US | claimed |
| WO-2021019523-A1 | A PROCESS FOR THE PREPARATION OF CARIPRAZINE SALT | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2021-02-04 | — | — | WO | disclosed |
| EP-3057942-B1 | 1,4-CYCLOHEXYLAMINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | CHEMO RES S L (ES) | 2017-06-14 | — | — | EP | disclosed |
| US-8314126-B2 | Disubstituted phenylpiperdines/piperazines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-11-20 | — | — | US | disclosed |
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2010-10-07 | — | — | US | disclosed |
| US-7763639-B2 | Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-07-27 | — | — | US | disclosed |
| EP-2204363-A1 | New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-07-07 | — | — | EP | disclosed |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, DRD4, DRD1 | DRD2 1/4885DRD3 4/4885KDM4E 1510/4885 |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, DRD4, DRD1 | DRD2 1/4885DRD3 4/4885KDM4E 1739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.